Taken together, these findings opened up the potential that DDR inhibition combined with radiation therapy could be a novel therapeutic approach for IDH1 R132H glioma patients harboring ATRX and TP53 inactivating mutations. This evidence concerns the gene TP53 and central nervous system cancer.